#ESMO2026
🚨New therapy alert
Based on the little retrospective data available, the shocking activity and the rarity of #DSRCT, we can consider trastuzumab deruxtecan as a standard of care for this disease.
20 浏览 · 2 赞 · 1 转发 · 0 回复
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgPatient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.org#ESMO26 🧬 Rapid Oral | DSRCT 💊 Trastuzumab deruxtecan (T-DXd) 👥 French retrospective series 🎯 ORR: 82% (9/11) 📈 Updated mPFS: 22 mo (n=12) ⏳ 12-mo OS: 69% 🔬 Responses despite HER2 IHC 0/1+ ⚠️ 1 treatment-related ILD death 💡 Remarkable activity! Prospective validation needed. @OncoAlert在 X 查看被引用的帖子
来源：César Serrano García · x.com